Stock Events

Stock Events

Bluebird bio 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is directly competing in the gene editing space, focusing on similar therapeutic areas as Bluebird bio, including hemoglobinopathies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in treating cystic fibrosis and other diseases, competing in the gene therapy market where Bluebird bio is also aiming to make an impact.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and gene therapies for rare genetic disorders, directly competing with Bluebird bio's gene therapy approach.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, targeting diseases in a similar manner to Bluebird bio.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing sector, focusing on delivering precise genomic modifications, competing with Bluebird bio's gene therapy strategies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is pioneering RNA interference (RNAi) therapies, which, while a different approach, target some of the same diseases as Bluebird bio.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics is advancing the field of gene editing with base editing technology, a direct competitor to Bluebird bio's gene therapy and editing efforts.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, with its broad interest in biopharmaceuticals, including gene therapy, competes across several areas, including those targeted by Bluebird bio.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space, particularly in oncology, overlapping with Bluebird bio's cancer therapy efforts.

About

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Andrew Obenshain
Employees
518
Country
United States
ISIN
US09609G1004

Listings

MU
DE
BLE.MU

0 Comments

Share your thoughts

FAQ

What is Bluebird bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Bluebird bio stocks are traded under the ticker BLE.MU.
How many employees does Bluebird bio have?▼
As of September 04, 2026, the company has 518 employees.
In which sector is Bluebird bio located?▼
Bluebird bio operates in the Other sector.
When did Bluebird bio complete a stock split?▼
The last stock split for Bluebird bio was on December 13, 2024 with a ratio of 1:20.
Where is Bluebird bio headquartered?▼
Bluebird bio is headquartered in Cambridge, United States.